Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial

被引:1
作者
Thomas Lodise
Joe Yang
Laura A. Puzniak
Ryan Dillon
Marin Kollef
机构
[1] Albany College of Pharmacy and Health Sciences,
[2] Merck & Co.,undefined
[3] Inc.,undefined
[4] Washington University School of Medicine,undefined
来源
Infectious Diseases and Therapy | 2020年 / 9卷
关键词
Ceftolozane/tazobactam; Hospital-acquired bacterial pneumonia; Hospitalization; Mechanical ventilation; Meropenem; Multidrug resistance; Ventilator-associated bacterial pneumonia;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:953 / 966
页数:13
相关论文
共 81 条
[1]  
Kalil AC(2016)Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society Clin Infect Dis 63 e61-e111
[2]  
Metersky ML(2010)Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Clin Infect Dis 51 S81-S87
[3]  
Klompas M(2017)Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in US medical centers, 2011 to 2015 Antimicrob Agents Chemother 61 e02083-16-1301
[4]  
Jones RN(2016)Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014 Infect Control Hosp Epidemiol 37 1288-02018
[5]  
Sader HS(2018)Treating nosocomial pneumonia: what’s new ERJ Open Res 4 00058-S17
[6]  
Castanheira M(2010)Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design Clin Infect Dis 51 S12-352
[7]  
Flamm RK(2019)A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia Crit Care Med 47 345-256
[8]  
Weiner LM(2012)Economic impact of ventilator-associated pneumonia in a large matched cohort Infect Control Hosp Epidemiol 33 250-1197
[9]  
Webb AK(2015) nosocomial pneumonia: impact of pneumonia classification Infect Control Hosp Epidemiol 36 1190-S125
[10]  
Limbago B(2010)Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia Clin Infect Dis 51 S120-S428